RICT 2007 - Drug Discovery and Selection
Cancer
04/07/2007
15:05
Discovery and Optimisation of Pyrazole Inhibitors of HSP90
Dr. Ted MCDONALD
(INSTITUTE FOR CANCER RESEARCH, Sutton, United Kingdom)
05/07/2007
09:05
Natural Product Inspired Isoform Selective Histone Deacetylase Inhibitors
Prof. A. GANESAN
(UNIVERSITY OF SOUTHAMPTON, Norwich, United Kingdom)
05/07/2007
10:45
The Discovery of AZD0530: A Novel, Oral, Highly Selective SRC Inhibitor with BCR-ABL Activity
Dr Laurent HENNEQUIN
(ASTRAZENECA, Reims, France)
05/07/2007
17:00
Metathesis and Synthesis of Anticancer Agents
Prof. Janine COSSY
(ESPCI PARISTECH, Paris, France)
Cardiovascular
04/07/2007
10:50
Opening the Gate to Novel Ion Channel Modulators and Innovative Anti-arrhythmics
Dr. Petra BLOM
(DEVGEN, Zwijnaarde, Belgium)
06/07/2007
09:05
In Silico Predicitions of Cardiovascular Safety - Beyond hERG
Dr. Luca FENU
(JOHNSON & JOHNSON PRD, Beerse, Belgium)
CNS
05/07/2007
15:50
The Discovery and Development of a Green Process for Radafaxine
Dr. Trevor J. GRINTER
(GLAXO SMITH KLINE, Tonbridge, United Kingdom)
06/07/2007
13:55
From Medicinal Chemistry to New Targets and New Drugs. Discovery of New Antiepileptic Drug Candidates.
Dr Benoit KENDA
(UCB, Braine-l'Alleud, Belgium)
Coagulation
04/07/2007
16:45
Synthesis and Structure-Activity Relationships of Oral Venous Antithrombotic Thioglycosylated Derivatives
Dr. Véronique BARBEROUSSE
(ABBOTT - LABORATOIRE FOURNIER, , France)
Hematology
06/07/2007
15:15
Discovery of Eltrombopag, a Small-Molecule Oral Thrombopoietin Receptor Agonist: a Modulator of a Protein-Protein Interaction
Dr. Juan LUENGO
(GLAXO SMITH KLINE, Collegeville, United States)
Metabolic Disorder
04/07/2007
11:25
From Compound to Targets to Compounds: The Example of the PPARs
Prof. Bart STAELS
(INSTITUT PASTEUR DE LILLE, Lille, France)
06/07/2007
10:45
Long Duration of Action by Design: Discovery of Degarelix, a Self-Depoting GnRH Blocker
Dr. Claudio SCHTEINGART
(FERRING RESEARCH INSTITUTE, San Diego, CA, United States)
06/07/2007
11:35
Concept and Development of Chimeric Molecules: Somatostatin –Dopamine Chimeras
Dr. Christophe THURIEAU
(GROUP IPSEN, Les Ulis, France)
06/07/2007
12:15
Therapeutic proteins : Role of Post-Translational Modifications in Structure-Function Relationships. Application to Monoclonal Antibodies and Coagulation Factors
Dr. Laurent SIRET
(LFB, Courtabœuf, France)
Protease Inhibitors
05/07/2007
09:40
The Evolution of a Series of Small Molecule Inhibitors of Neutral Endopeptidase
Dr David PRYDE
(PFIZER GLOBAL R&D, Sandwich, United Kingdom)
<Previous page


Organized under the auspices of


Sponsored by the European Federation for Medicinal Chemistry

With the support of

Sponsors

Media Partners